vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and CALERES INC (CAL). Click either name above to swap in a different company.
ALNYLAM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($1.2B vs $790.1M, roughly 1.5× CALERES INC). ALNYLAM PHARMACEUTICALS, INC. runs the higher net margin — 17.6% vs 0.3%, a 17.3% gap on every dollar of revenue. On growth, ALNYLAM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (96.4% vs 6.6%). Over the past eight quarters, ALNYLAM PHARMACEUTICALS, INC.'s revenue compounded faster (33.0% CAGR vs 6.5%).
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Caleres Inc. is an American footwear company that owns and operates a variety of footwear brands. Its headquarters is located in Clayton, Missouri, a suburb of St. Louis. The company was founded in 1878 as Bryan, Brown & Company in St. Louis, though it underwent several name changes. The Hamilton-Brown Shoe Company was the largest manufacturer of shoes in America in the early 20th century, but it went bankrupt in June 1939.
ALNY vs CAL — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $790.1M |
| Net Profit | $206.0M | $2.4M |
| Gross Margin | 82.2% | 41.8% |
| Operating Margin | 23.0% | 1.5% |
| Net Margin | 17.6% | 0.3% |
| Revenue YoY | 96.4% | 6.6% |
| Net Profit YoY | — | -94.2% |
| EPS (diluted) | $1.51 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $790.1M | ||
| Q3 25 | $1.2B | $658.5M | ||
| Q2 25 | $773.7M | $614.2M | ||
| Q1 25 | $594.2M | $639.2M | ||
| Q4 24 | $593.2M | $740.9M | ||
| Q3 24 | $500.9M | $683.3M | ||
| Q2 24 | $659.8M | $659.2M |
| Q1 26 | $206.0M | — | ||
| Q4 25 | $186.4M | $2.4M | ||
| Q3 25 | $251.1M | $6.7M | ||
| Q2 25 | $-66.3M | $6.9M | ||
| Q1 25 | $-57.5M | $4.9M | ||
| Q4 24 | $-83.8M | $41.4M | ||
| Q3 24 | $-111.6M | $30.0M | ||
| Q2 24 | $-16.9M | $30.9M |
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | 41.8% | ||
| Q3 25 | 84.2% | 43.4% | ||
| Q2 25 | 81.6% | 45.4% | ||
| Q1 25 | 88.2% | 43.0% | ||
| Q4 24 | 82.7% | 44.1% | ||
| Q3 24 | 83.6% | 45.5% | ||
| Q2 24 | 89.8% | 46.9% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 12.0% | 1.5% | ||
| Q3 25 | 29.5% | 1.4% | ||
| Q2 25 | -2.1% | 1.9% | ||
| Q1 25 | 3.0% | 1.2% | ||
| Q4 24 | -17.7% | 7.7% | ||
| Q3 24 | -15.4% | 6.2% | ||
| Q2 24 | 7.4% | 6.5% |
| Q1 26 | 17.6% | — | ||
| Q4 25 | 17.0% | 0.3% | ||
| Q3 25 | 20.1% | 1.0% | ||
| Q2 25 | -8.6% | 1.1% | ||
| Q1 25 | -9.7% | 0.8% | ||
| Q4 24 | -14.1% | 5.6% | ||
| Q3 24 | -22.3% | 4.4% | ||
| Q2 24 | -2.6% | 4.7% |
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | $0.07 | ||
| Q3 25 | $1.84 | $0.20 | ||
| Q2 25 | $-0.51 | $0.21 | ||
| Q1 25 | $-0.44 | $0.17 | ||
| Q4 24 | $-0.66 | $1.19 | ||
| Q3 24 | $-0.87 | $0.85 | ||
| Q2 24 | $-0.13 | $0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $34.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $616.8M |
| Total Assets | $5.1B | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $34.0M | ||
| Q3 25 | $1.5B | $191.5M | ||
| Q2 25 | $1.1B | $33.1M | ||
| Q1 25 | $1.0B | $29.6M | ||
| Q4 24 | $966.4M | $33.7M | ||
| Q3 24 | $1.1B | $51.8M | ||
| Q2 24 | $968.5M | $30.7M |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $789.2M | $616.8M | ||
| Q3 25 | $233.9M | $613.3M | ||
| Q2 25 | $250.6M | $605.2M | ||
| Q1 25 | $115.4M | $599.0M | ||
| Q4 24 | $67.1M | $598.3M | ||
| Q3 24 | $32.4M | $606.1M | ||
| Q2 24 | $-3.1M | $570.3M |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $2.1B | ||
| Q3 25 | $4.9B | $2.2B | ||
| Q2 25 | $4.6B | $1.9B | ||
| Q1 25 | $4.2B | $1.9B | ||
| Q4 24 | $4.2B | $2.0B | ||
| Q3 24 | $4.2B | $2.0B | ||
| Q2 24 | $4.0B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.2M |
| Free Cash FlowOCF − Capex | — | $-12.4M |
| FCF MarginFCF / Revenue | — | -1.6% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | -0.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $163.6M | $-1.2M | ||
| Q3 25 | $325.1M | $47.3M | ||
| Q2 25 | $153.7M | $-5.7M | ||
| Q1 25 | $-118.3M | $28.7M | ||
| Q4 24 | $-94.7M | $-39.8M | ||
| Q3 24 | $43.7M | $79.6M | ||
| Q2 24 | $124.2M | $36.1M |
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-12.4M | ||
| Q3 25 | $313.0M | $35.0M | ||
| Q2 25 | $139.4M | $-26.2M | ||
| Q1 25 | $-127.3M | $18.0M | ||
| Q4 24 | $-103.8M | $-57.4M | ||
| Q3 24 | $39.5M | $68.5M | ||
| Q2 24 | $116.1M | $26.3M |
| Q1 26 | — | — | ||
| Q4 25 | 12.8% | -1.6% | ||
| Q3 25 | 25.1% | 5.3% | ||
| Q2 25 | 18.0% | -4.3% | ||
| Q1 25 | -21.4% | 2.8% | ||
| Q4 24 | -17.5% | -7.7% | ||
| Q3 24 | 7.9% | 10.0% | ||
| Q2 24 | 17.6% | 4.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 1.4% | ||
| Q3 25 | 1.0% | 1.9% | ||
| Q2 25 | 1.8% | 3.3% | ||
| Q1 25 | 1.5% | 1.7% | ||
| Q4 24 | 1.5% | 2.4% | ||
| Q3 24 | 0.8% | 1.6% | ||
| Q2 24 | 1.2% | 1.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.88× | -0.50× | ||
| Q3 25 | 1.29× | 7.05× | ||
| Q2 25 | — | -0.81× | ||
| Q1 25 | — | 5.82× | ||
| Q4 24 | — | -0.96× | ||
| Q3 24 | — | 2.66× | ||
| Q2 24 | — | 1.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
CAL
| Brand Portfolio | $383.7M | 49% |
| Landed Wholesale | $148.1M | 19% |
| Wholesale E Commerce | $75.0M | 9% |
| Ecommerce | $68.8M | 9% |
| Stuart Weitzman Brand | $45.8M | 6% |
| Landed Wholesale Ecommerce Drop Ship | $30.6M | 4% |
| First Cost Wholesale | $14.9M | 2% |
| Clt Brand Solutions | $10.2M | 1% |
| License And Royalty | $2.1M | 0% |
